Goldman Sachs Maintains Buy on uniQure, Lowers Price Target to $51
Goldman Sachs maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target from $59 to $51.
SVB Leerink Maintains Outperform on uniQure, Lowers Price Target to $56
SVB Leerink analyst Joseph Schwartz maintains uniQure (NASDAQ:QURE) with a Outperform and lowers the price target from $71 to $56.
uniQure Q1 EPS $(1.00) Down From $(0.91) YoY, Sales $1.80M Up From $454.00K YoY
uniQure (NASDAQ:QURE) reported quarterly losses of $(1.00) per share. This is a 9.89 percent decrease over losses of $(0.91) per share from the same period last year. The company reported $1.80 million in sales this
Akari Therapeutics Appoints Rachelle Jacques As President And Chief Executive Officer
Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Overview Of Value Stocks In The Healthcare Sector
Understanding Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
5 Value Stocks In The Healthcare Sector
Understanding Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
